9-2015

*Borrelia burgdorferi* RevA Significantly Affects Pathogenicity and Host Response in the Mouse Model of Lyme Disease

Rebecca Byram  
*Centers for Disease Control and Prevention*

Robert A. Gaultney  
*University of North Dakota*

Angela M. Floden  
*University of North Dakota*

Christopher Hellekson  
*University of North Dakota*

Brandee L. Stone  
*University of North Dakota*

See next page for additional authors

Follow this and additional works at: https://uknowledge.uky.edu/microbio_facpub

Part of the [Medical Immunology Commons](https://uknowledge.uky.edu/medicalimmunology), [Medical Microbiology Commons](https://uknowledge.uky.edu/medicalmicrobiology), and the [Molecular Genetics Commons](https://uknowledge.uky.edu/moleculargenetics)

Repository Citation

Byram, Rebecca; Gaultney, Robert A.; Floden, Angela M.; Hellekson, Christopher; Stone, Brandee L.; Bowman, Amy; Stevenson, Brian; Johnson, Barbara J. B.; and Brissette, Catherine A., "*Borrelia burgdorferi* RevA Significantly Affects Pathogenicity and Host Response in the Mouse Model of Lyme Disease" (2015). Microbiology, Immunology, and Molecular Genetics Faculty Publications. 80.  
https://uknowledge.uky.edu/microbio_facpub/80

This Article is brought to you for free and open access by the Microbiology, Immunology, and Molecular Genetics at UKnowledge. It has been accepted for inclusion in Microbiology, Immunology, and Molecular Genetics Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Authors
Rebecca Byram, Robert A. Gaultney, Angela M. Floden, Christopher Hellekson, Brandee L. Stone, Amy Bowman, Brian Stevenson, Barbara J. B. Johnson, and Catherine A. Brissette

*Borrelia burgdorferi* RevA Significantly Affects Pathogenicity and Host Response in the Mouse Model of Lyme Disease

Notes/Citation Information
Published in *Infection and Immunity*, v. 83, no. 9, p. 3675-3683.

Copyright © 2015, American Society for Microbiology. All Rights Reserved.

The copyright holders have granted the permission for posting the article here.

Digital Object Identifier (DOI)
http://dx.doi.org/10.1128/IAI.00530-15

This article is available at UKnowledge: https://uknowledge.uky.edu/microbio_facpub/80
Borrelia burgdorferi, the causative agent of Lyme disease, is a vector-borne pathogen that successfully colonizes both ticks and a variety of vertebrate hosts. In mammals, B. burgdorferi is frequently found associated with connective tissues (1–13), and the bacterium is often detected in cartilaginous or collagen-rich tissues, such as skin and joints (6, 7, 9, 11–18). Adhesins expressed by B. burgdorferi facilitate interactions with these tissues. B. burgdorferi expresses a plethora of outer surface proteins that interact with numerous components of the extracellular matrix (ECM), such as fibronectin, decorin, and integrins (19–23). The attachment of B. burgdorferi to the ECM is likely critical for pathogenesis and persistence in mammals. Indeed, for many of these adhesins, deletion mutants have significant defects in infectivity, fail to disseminate widely in the host, or have other effects on disease, such as alterations in the severity of arthritis (24–27).

The interactions of B. burgdorferi with fibronectin are facilitated by several distinct bacterial surface proteins, including BBK32, RevA, BB0347, and CspA (BbCRASP-1) (28–31). The redundancy in adhesins makes it difficult to dissect the role of each B. burgdorferi fibronectin binding protein in the pathogenesis of Lyme disease. For example, real-time microscopic imaging in live mice revealed a significant role for BBK32 in interactions with host vasculature, yet bbk32 mutants are still able to infect mammals (32).

RevA is a 19-kDa surface protein encoded on the circular plasmid 32 (cp32) family of plasmids (33). RevA expression is elevated during mammalian infection over its expression in the tick vector, suggesting a role in pathogenesis (30, 34–36). RevA binds to fibronectin, and anti-RevA antibodies block the binding of whole B. burgdorferi bacteria to fibronectin (30). RevA is antigenic, as evidenced by the fact that both mice and human Lyme disease patients produce antibodies against RevA (36, 37). Antibodies against RevA are bactericidal in vitro, and passive immunization with anti-RevA antibodies prevents infection (38). However, mice vaccinated with recombinant RevA protein were not protected when challenged with B. burgdorferi by needle or tick bite (38).

Analysis of RevA has been complicated by the fact that two separate revA genes are present in the B31 type strain, revA1 on cp32-1 and revA6 on cp32-6. The mature amino acid sequences of the two encoded RevA proteins are identical, however. Intriguingly, a revA1 mutant uncovered in a transposon mutagenesis study demonstrated an infectivity deficit in dissemination (39). To further elucidate the function of RevA and its role in the pathogenesis of B. burgdorferi, we created a double revA deletion mutant and characterized its infectious properties.

MATERIALS AND METHODS

Bacteria. B. burgdorferi strain B31-A3 is an infectious clone of the sequenced type strain (40, 41) that contains all parental plasmids except cp9 (42). Bacteria were grown at 34°C to densities of approximately 1 × 10⁷ cells/ml in modified Barbour-Stoenner-Kelly (BSK-II) medium supplemented with 6% rabbit serum (43). Total DNA (genomic and plasmid DNA) was isolated using a DNeasy blood and tissue kit (Qiagen, Valencia, CA). Plasmid contents were determined by multiplex PCR as described by Bunikis et al. (44).

Generation of revA deletion mutant and complemented mutant clones. B. burgdorferi strain B31-A3 has 2 copies of the revA gene: revA1 on plasmid cp32-1 (open reading frame [ORF] bbp27) and revA6 (ORF bbm27) on plasmid cp32-6. To create a doubly deleted mutant, the revA1

B. burgdorferi RevA Significantly Affects Pathogenicity and Host Response in the Mouse Model of Lyme Disease

Rebecca Byram,a Robert A. Gaultney,b Angela M. Floden,b Christopher Hellekson,b Brandee L. Stone,b Amy Bowman,c Brian Stevenson,b Barbara J. B. Johnson,a Catherine A. Brissetteb

Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA; Department of Basic Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, USA; Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky School of Medicine, Lexington, Kentucky, USA

The Lyme disease spirochete, Borrelia burgdorferi, expresses RevA and numerous outer surface lipoproteins during mammalian infection. As an adhesin that promotes bacterial interaction with fibronectin, RevA is poised to interact with the extracellular matrix of the host. To further define the role(s) of RevA during mammalian infection, we created a mutant that is unable to produce RevA. The mutant was still infectious to mice, although it was significantly less well able to infect cardiac tissues. Complementation of the mutant with a wild-type revA gene restored heart infectivity to wild-type levels. Additionally, revA mutants led to increased evidence of arthritis, with increased fibrotic collagen deposition in tibiotarsal joints. The mutants also induced increased levels of the chemokine CCL2, a monocyte chemoattractant, in serum, and this increase was abolished in the complemented strain. Therefore, while revA is not absolutely essential for infection, deletion of revA had distinct effects on dissemination, arthritis severity, and host response.
region was first PCR amplified with the primers listed in Table 1 and then cloned into the TOPO XL vector (Fig. 1A). Restriction enzyme sites (Sall) were created, and the revA open reading frame was deleted, by inverse PCR. A streptomycin resistance cassette was first ligated into the Sall site and then introduced into B. burgdorferi B31-A3 by electroporation (45). The revA6 locus was deleted in a similar manner (using a kanamycin cassette), and the final construct was introduced into the ΔrevA1 mutant. Deletion of both revA loci was confirmed by PCR (primers listed in Table 1) and bidirectional Sanger sequencing, and the double deletion mutant was designated B31-A3ΔΔrevA1ΔrevA6.

For complementation, the wild-type revA1 gene was cloned into a B. burgdorferi-Escherichia coli shuttle plasmid under the control of the constitutive promoter PflgB. Briefly, pBSV2-G (46) was modified by overlap extension PCR mutagenesis to delete the existing multiple cloning site and BamHI, PstI, and KpnI cleavage sites (Fig. 1C). The revA1 gene, without its native promoter, was PCR amplified using primers with added BamHI and PstI sites and was then cloned into pBSL715. This insertion was verified by PCR and bidirectional Sanger sequencing (Davis Sequencing). The new construct, pBSL715revA1, was introduced into B31-A3ΔΔrevA1ΔrevA6 (the revA double deletion mutant) by electroporation (45). Several individual clones were isolated by pour plating in B. burgdorferi B31-A3 by electroporation (45). To initiate tick infection studies, female C3H/HeN mice (4 to 6 weeks old) were infected by subcutaneous injection with 1 × 10^7, 1 × 10^6, or 1 × 10^5 bacteria of strain B31-A3, the B31-A3ΔrevA1ΔrevA6 mutant, or the complemented strain, B31-A3ΔΔrevA1ΔrevA6/pBSL715revA1, from mid-exponential-phase cultures grown at 34°C. Cultures were harvested at 1 × 10^7 bacteria/ml. Infection of mice was confirmed by analysis of serum samples by enzyme-linked immunosorbent assays (ELISAs) for antibodies directed against B. burgdorferi whole-cell lysates as described previously (30, 38). Two weeks after infection, ear pinnae, hearts, bladders, skin from the inoculation site, and tibiotarsal joints were collected and were either frozen for DNA extraction and quantitative PCR (qPCR) or cultured in BSK-II medium plus 6% rabbit serum and 50 μg/ml rifampin.

To initiate tick infection studies, female C3H/HeN mice (4 to 6 weeks old) were infected by subcutaneous injection of 1 × 10^6 bacteria of strain B31-A3 or the revA-deficient mutant from mid-exponential-phase cultures grown at 34°C. Cultures were harvested at 1 × 10^7 bacteria/ml. Infection of mice was confirmed by analysis of serum samples by enzyme-linked immunosorbent assays (ELISAs) for antibodies directed against B. burgdorferi whole-cell lysates as described previously (30, 38). Two weeks after infection, ear pinnae, hearts, bladders, skin from the inoculation site, and tibiotarsal joints were collected and were either frozen for DNA extraction and quantitative PCR (qPCR) or cultured in BSK-II medium plus 6% rabbit serum and 50 μg/ml rifampin.

To initiate tick infection studies, female C3H/HeN mice (4 to 6 weeks old) were infected by subcutaneous injection of 1 × 10^6 bacteria of strain B31-A3 or the revA-deficient mutant from mid-exponential-phase cultures grown at 34°C. Cultures were harvested at 1 × 10^7 bacteria/ml. Infection of mice was confirmed by analysis of serum samples by enzyme-linked immunosorbent assays (ELISAs) for antibodies directed against B. burgdorferi whole-cell lysates as described previously (30, 38). Two weeks after infection, ear pinnae, hearts, bladders, skin from the inoculation site, and tibiotarsal joints were collected and were either frozen for DNA extraction and quantitative PCR (qPCR) or cultured in BSK-II medium plus 6% rabbit serum and 50 μg/ml rifampin.

To initiate tick infection studies, female C3H/HeN mice (4 to 6 weeks old) were infected by subcutaneous injection of 1 × 10^6 bacteria of strain B31-A3 or the revA-deficient mutant from mid-exponential-phase cultures grown at 34°C. Cultures were harvested at 1 × 10^7 bacteria/ml. Infection of mice was confirmed by analysis of serum samples by enzyme-linked immunosorbent assays (ELISAs) for antibodies directed against B. burgdorferi whole-cell lysates as described previously (30, 38). Two weeks after infection, ear pinnae, hearts, bladders, skin from the inoculation site, and tibiotarsal joints were collected and were either frozen for DNA extraction and quantitative PCR (qPCR) or cultured in BSK-II medium plus 6% rabbit serum and 50 μg/ml rifampin.

**Infection of mice and ticks.** For studies of 50% infective doses (ID_{50}) and tissue dissemination, female C3H/HeN mice (4 to 6 weeks old) were infected by subcutaneous injection with 1 × 10^2, 1 × 10^3, 1 × 10^4, or 1 × 10^5 bacteria of strain B31-A3, the B31-A3ΔrevA1ΔrevA6 mutant, or the complemented strain, B31-A3ΔΔrevA1ΔrevA6/pBSL715revA1, from mid-exponential-phase cultures grown at 34°C. Cultures were harvested at 1 × 10^7 bacteria/ml. Infection of mice was confirmed by analysis of serum samples by enzyme-linked immunosorbent assays (ELISAs) for antibodies directed against B. burgdorferi whole-cell lysates as described previously (30, 38). Two weeks after infection, ear pinnae, hearts, bladders, skin from the inoculation site, and tibiotarsal joints were collected and were either frozen for DNA extraction and quantitative PCR (qPCR) or cultured in BSK-II medium plus 6% rabbit serum and 50 μg/ml rifampin.
After 96 h, the ticks had fully engorged and naturally dropped off the mice. Immediately after the completion of feeding, cohorts of approximately 30 engorged larvae from each mouse were analyzed by qPCR (primers are given in Table 1) for the acquisition of *B. burgdorferi*. The remainder of the ticks were returned to the humidified chamber and were allowed to molt to the nymphal stage. Approximately 3 weeks after ecdysis, the infected nymphs were allowed to feed on naïve female C3H/HeN mice. Mice infected through feeding by infected nymphs were killed 2 weeks after the completion of tick feeding. Ear pinnae, hearts, bladders, and tibiotarsal joints were processed for DNA extraction and culture. For arthritis development, female C3H/HeN mice (3 to 4 weeks old) were infected by injection into the left footpad of 1/10^9 or 1/10^4 bacteria of strain B31-A3, the B31-A3ΔrevAΔrevA6 mutant, or the complemented strain from mid-exponential-phase cultures grown at 34°C.

**Measurement of tibiotarsal joints.** Joint measurements were taken for both ankles with a digital metric caliper (General Tools, Montreal, QC, Canada) at 0, 2, and 4 weeks postinfection. Measurements were taken in the anterior-to-posterior position with the knee extended, through the thickest portion of the ankle (47). Three measurements were taken per time point and were averaged. A researcher blinded to the strain of *B. burgdorferi* took the measurements, while a second researcher recorded the results. The percentage of change in ankle diameter was determined by subtracting the preinfection joint diameter from the measurements taken at weeks 2 and 4 [e.g., (individual ankle measurement at 2 weeks/individual ankle measurement at baseline) × 100].

**Histology of tibiotarsal joints.** At 4 weeks postinfection, mice were sacrificed and the tibiotarsal joints collected for histopathology. The joints were first decalcified and then fixed in 10% neutral buffered formalin. Sections from the decalcified joints were embedded in paraffin and were stained with hematoxylin and eosin (H&E; AML Laboratories, Baltimore, MD). Sections were scored blindly by a veterinary pathologist (North Dakota State University [NDSU], Fargo, ND) from 0 to 5, as follows: 0, no inflammation; 1, minimal change; 2, mild change (1 to 25% of the area infiltrated with leukocytes); 3, moderate change (25 to 50% of the area infiltrated with leukocytes, often with synovial hyperplasia and/or fibrosis); 4, severe change (including more than 50% infiltrating leukocytes,

---

**FIG 1 Construction of the revA-deficient mutant.**

(A) Schematic of mutant construction. See Materials and Methods for details of cloning. (B) PCR confirmation of revA deletions by use of flanking primers for the revA6 locus (lanes 1 to 4) and primers for aad (lanes 5 to 7). Lanes 1 and 5, B31-A3ΔrevAΔrevA6; lanes 2 and 6, the parental strain, B31-A3; lane 3, cloning plasmid control (with the whole flanking region plus revA and the kan cassette); lane 4, no template; lane 7, cloning plasmid control (with the whole flanking region plus revA and the aad cassette). L, ladder. (C) Schematic of construction of the revA complement vector. MCS, multiple cloning site; RBS, ribosome-binding site. (D) Immunoblotting for RevA protein in whole-cell lysates. Lane 1, B31-A3 (wild type [WT]); lane 2, overloaded B31-A3ΔrevAΔrevA6 (knockout [KO]); lane 3, complemented strain. OspC serves as a loading control.
syndesmophilic hyperplasia, and fibrosis); 5, most severe change (characteristics of score 4 plus exudates within the joint or tendon sheath). For collagen staining, paraffin-embedded H&E-stained slides were deparaffinized and placed in phosphate-buffered saline (PBS). The slides were then stained with Masson’s trichrome stains (Sigma-Aldrich) according to the manufacturer’s standard procedure. Slides were first dehydrated with increasing concentrations of ethanol-water solutions and then equilibrated in a xylene-ethanol solution (1:1, by volume) followed by 100% xylene. Coverslips were then placed on the slides by using Permount (Thermo Fisher). Sections from at least 3 mice per infection strain were examined.

ELISA. Mouse blood was drawn from the saphenous vein and was collected in heparin-coated tubes. Blood samples were centrifuged (6,000 × g) to remove red blood cells, and the serum was stored at −20°C. To measure mouse IgM or IgG against B. burgdorferi, 96-well plates were coated overnight with 100 µl/well of 10 µg/ml B. burgdorferi lysate (mid-log-phase B. burgdorferi cultures, pelleted and washed 3 times in PBS) in carbonate coating buffer (0.32 g Na₂CO₃ and 0.586 g NaHCO₃ per 200 ml pH 9.6) at 4°C. Room temperature plates were washed three times with PBS containing 0.05% Tween 20 (by volume) (PBS-T). Wells were first blocked for 2 h at room temperature with PBS containing 10% fetal bovine serum and then washed three times with PBS-T. At the time of the assay, a 1:100 dilution of serum was placed on the plate and was incubated for 2 h at 37°C. Wells were first washed three times with PBS-T and then incubated for 1 h at room temperature with a horseradish peroxidase (HRP)-conjugated goat anti-serum against mouse IgM (Pierce) or IgG (GE Healthcare, Piscataway, NJ) diluted to 1:5,000 in PBS. Color development was performed by adding a tetramethylbenzidine substrate (TMB; Thermo Fisher Scientific, Waltham, MA) for 15 min and was stopped by the addition of an equal volume of 2 N sulfuric acid. Commercial ELISA kits were used to measure mouse chemokines according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN).

Analysis of B. burgdorferi loads in mouse tissues. Total DNA was extracted from tissue samples by using a DNeasy kit according to the manufacturer’s instructions (Qiagen). Frozen mouse tissue samples (20 mg) were first mixed with sterile single-use razor blades on a DNA/ DNase-free glass surface and were resuspended in Buffer ATL with proteinase K for overnight digestion at 56°C as recommended by the manufacturer (Qiagen). For ticks, cohorts of 30 fed larvae were processed according to the method of Jutras et al. (48). qPCR was performed using a Bio-Rad CFX96 thermal cycler and Bio-Rad SYBR green mix. All DNA samples were analyzed in triplicate. Each run included a sample that lacked a template in order to test for DNA contamination of reagents. The oligonucleotide primers used for amplification of B. burgdorferi recA (nTM17F and nTM17R) (49), Ixodes scapularis 16S rRNA, B. burgdorferi flaB (48), and mouse nidogen were given in Table 1. Reaction conditions consisted of a 10-min initial denaturation step at 95°C; 40 cycles of 95°C for 1 s and 55°C (for recA) or 60°C (for nidogen) for 1 min; 95°C for 1 min; 60°C for 1 min; and melting analysis starting at 60°C and increasing by increments of 0.3°C, with a hold at each temperature for 10 s. Tenfold serial dilutions of B. burgdorferi genomic DNA, mouse genomic DNA, or Ixodes genomic DNA were included in every assay for each primer set. This enabled the generation of standard curves from which the amount of DNA present in each sample could be calculated by using Bio-Rad MyiQ2 software. The same software package was also used for melting-curve analyses. To verify amplicon sizes and purities, all products were separated by agarose gel electrophoresis, and DNA was visualized with ethidium bromide. Average values obtained from triplicate runs of each DNA sample for B. burgdorferi recA copies or flaB copies were calculated relative to the average triplicate value for the mouse nidogen or I. scapularis 16S rRNA housekeeping gene from the same DNA preparation. Statistical analyses of data were performed using Student’s t test and assuming unequal variances.

**Table 2** ID₅₀ of wild-type and revA-deficient B. burgdorferi strains

<table>
<thead>
<tr>
<th>Strain and inoculum</th>
<th>No. culture positive/total no.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mice</td>
</tr>
<tr>
<td>B31-A3</td>
<td></td>
</tr>
<tr>
<td>10⁵</td>
<td>6/6</td>
</tr>
<tr>
<td>10⁴</td>
<td>10/10</td>
</tr>
<tr>
<td>10³</td>
<td>10/10</td>
</tr>
<tr>
<td>10²</td>
<td>0/6</td>
</tr>
<tr>
<td>B31-A3ΔrevA1ΔrevA6</td>
<td></td>
</tr>
<tr>
<td>10⁵</td>
<td>6/6</td>
</tr>
<tr>
<td>10⁴</td>
<td>8/10</td>
</tr>
<tr>
<td>10³</td>
<td>8/10</td>
</tr>
<tr>
<td>10²</td>
<td>0/6</td>
</tr>
</tbody>
</table>

* Mice were infected subcutaneously with increasing inocula of the B. burgdorferi parental strain B31-A3 or the B31-A3ΔrevA1ΔrevA6 mutant. Mice were sacrificed 2 weeks postinfection, and organs were cultured.

*Including bladders, hearts, ears, and tibiotarsal joints.

**RESULTS**

Generation of B. burgdorferi revA double deletion and complemented strains. The B. burgdorferi type strain, B31, naturally carries 2 nearly identical copies of the revA gene: revA1 on plasmid cp32-1 and revA6 on plasmid cp32-6. The amino acid sequences of the mature RevA1 and RevA6 proteins are identical. The revA loci were sequentially deleted by allelic exchange, as diagramed in Fig. 1A, creating strain B31-A3ΔrevA1ΔrevA6. A schematic of the construction of the mutant is shown in Fig. 1A. The deletion of both copies of revA through allelic exchange was confirmed by PCR (Fig. 1B).

To demonstrate that any observed phenotypes of the mutant strain were due to revA deletion only, a revA trans-complemented strain was also constructed (B31-A3ΔrevA1ΔrevA6/pBLS715revA). The relevant sequences of both strains were confirmed by PCR and sequencing. The inability of the mutant to produce RevA and the production of RevA by the complemented strain were confirmed by immunoblotting (Fig. 1D).

Effect of RevA deletion on infectivity. To assess the contribution of RevA to the pathogenic process, we tested the ability of the mutant bacterium to complete each stage of the natural infection cycle. B31-A3ΔrevA1ΔrevA6 mutant bacteria were first assessed for their ability to infect mammals. Cohorts of mice were inoculated with serially diluted bacteria, ranging from 10 to 10⁵ spirochetes per animal (50). Wild-type B. burgdorferi generally exhibits ID₅₀ of 10 to 100 bacteria in mice (51–53). We found no differences in the ID₅₀ between the wild-type and revA-deficient B. burgdorferi strains (Table 2).

Experience with other B. burgdorferi mutants has demonstrated subtle defects in infectivity, such as impaired dissemination or differences in tissue pathology (see, e.g., references 25 and 54). Therefore, we also determined the ability of revA-deficient bacteria to disseminate to distal organs. We found that the B31-A3ΔrevA1ΔrevA6 mutant was significantly less able to colonize heart tissues (P = 0.003) than the wild-type strain (Fig. 2A). This defect was restored upon complementation. No significant defects were observed for tibiotarsal joint colonization (Fig. 2B).

Noting that other borreliad adhesins have been found to have an impact on tissue-specific pathology, we tested the effects of RevA deficiency on arthritis severity. Cohorts of C3H/HeN mice...
were injected subcutaneously or in the left footpad with $10^3$ or $10^4$ B. burgdorferi B31-A3 or B31-A3ΔrevA1ΔrevA6 mutant bacteria. Tibiotarsal joint (ankle) thickness was measured before and after infection. Mice that were injected in the footpad with $10^3$ B31-A3ΔrevA1ΔrevA6 bacteria showed significantly greater ankle thickness at 4 weeks postinfection ($P < 0.001$) (Fig. 3A). No significant differences were apparent following inoculation with the higher dose ($10^4$ bacteria) (Fig. 3B). No significant swelling of the right ankle was noted for the footpad-injected mice (data not shown). For all mice injected subcutaneously, ankle thickness increased over time, but there were no differences between B31-A3, the revA-deficient mutant, and the complemented strain (data not shown).

Histological examination of tibiotarsal joints was then performed, for more precise evaluation of arthritis. Tibiotarsal joints were collected after 4 weeks of infection, sectioned, and stained with hematoxylin and eosin. Each section was blindly examined by a veterinary pathologist and was given a score ranging from 0 to 5, with 0 indicating normal tissue and 5 representing the most severe lesions. In mice infected with either the parental strain or the revA-deficient mutant, all sections showed chronic active inflammation with infiltration of plasma cells, lymphocytes, and macrophages, as well as a proliferative response in the periarticular connective tissue (Table 3). However, joints from mice infected with the revA-deficient mutant had lower average histopathology scores than joints from mice infected with the parental strain, B31-A3 (Table 3). Yet Masson’s trichome stain for collagen

<table>
<thead>
<tr>
<th>Strain and inoculum</th>
<th>No. of mice</th>
<th>Histopathology score</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>8</td>
<td>0.57 ± 0.27</td>
</tr>
<tr>
<td>B31-A3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$10^3$</td>
<td>8</td>
<td>4.50 ± 0.26</td>
</tr>
<tr>
<td>$10^4$</td>
<td>4</td>
<td>4.00 ± 0.58</td>
</tr>
<tr>
<td>revA mutant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$10^3$</td>
<td>5</td>
<td>3.10 ± 0.50</td>
</tr>
<tr>
<td>$10^4$</td>
<td>7</td>
<td>3.30 ± 0.42</td>
</tr>
<tr>
<td>revA-complemented strain</td>
<td>3</td>
<td>0.33 ± 0.10</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>0.33 ± 0.10</td>
</tr>
</tbody>
</table>

a The left footpad of each mouse was injected with B. burgdorferi or the control (PBS).

b Each section was given a score ranging from 0 to 5, with 0 indicating normal tissue and 5 representing the most severe lesions. Each data point represents the average score per section ± the standard error of the mean.
revealed more fibrotic connective tissue deposition in the joints of mice infected with the revA-deficient mutant, extending into and obliterating the entire joint space (Fig. 4B). In contrast, collagen staining was dense and regular, with little fibrosis inside the joint space, in mice infected with either B31-A3 or the revA-complemented strain (Fig. 4A and C). Mice infected with the complemented strain had no demonstrable pathology in the ankle joint. These data suggest that revA deletion results in increased levels of edema and remodeling in the affected joint.

Effect of RevA deletion on systemic chemokine production. To determine whether the systemic levels of cytokines or chemokines elicited in revA-deficient mutant- and B31-A3-infected mice differed, serum was collected from all revA-deficient mutant- and B31-A3 infected mice at the time of euthanasia. An initial multi-analyte screen for cytokines and chemokines suggested differences between the levels of tumor necrosis factor alpha (TNF-α), interleukin 17 (IL-17), and CCL-2 in the sera of animals infected with the RevA-deficient strain and those infected with the wild-type strain (data not shown). ELISAs indicated that the revA-deficient mutant induced significantly higher systemic CCL-2 levels at all inocula than did either the wild-type B31-A3 or the complemented mutant (P = 0.014) (Fig. 5). There were no significant differences in TNF-α or IL-17 induction for any strain.

Acquisition and transmission by ticks. The potential impacts of RevA deficiency throughout the remainder of the mouse-tick infectious cycle were also examined. First, mice infected with either B31-A3 or B31-A3ΔrevA1ΔrevA6 were fed upon by I. scapularis tick larvae. Immediately after the completion of feeding, cohorts of approximately 30 engorged larvae from each mouse were analyzed by qPCR, according to established procedures (30, 42, 55, 56), for the acquisition of B. burgdorferi. No significant differences in acquisition were detected (Table 4). We then tested the ability of those bacteria to colonize ticks and to be transmitted to mice. Three weeks after molting, ticks were allowed to feed on naïve mice. All naïve mice (6 each for the wild-type strain and B31-A3ΔrevA1ΔrevA6) became infected, as determined by detection of anti-B. burgdorferi IgG by ELISA and by positive culture of hearts, ears, and joints (Table 4). Taken together, these data dem-

FIG 4 Proliferative response in periarticular connective tissue. Tibiotarsal sections from infected mice were stained for collagen. (A) Section from a B31-A3-infected mouse with patent synovial spaces and clear demarcations of bone and dense, regular connective tissue. (B) Section from a B31-A3ΔrevA1ΔrevA6 mutant-infected mouse with apparent degeneration of bone and infiltration of connective tissue into the joint space. (C) Section from a mouse infected with the complemented strain. Three individual sections from 3 infected animals were observed per infection strain; representative slides are shown. Arrows indicate collagen staining at the edge of the joint space.

FIG 5 The revA-deficient mutant induces higher systemic CCL-2 levels than the wild-type strain. Blood was collected at the time of sacrifice from mice infected with B. burgdorferi (B31-A3, the B31-A3ΔrevA1ΔrevA6 mutant, or the complemented strain; subcutaneous dose of 10⁵, 10⁶, or 10⁷ bacteria). Red blood cells were pelleted, and serum was frozen at −80°C. A commercial sandwich ELISA was used to assay CCL-2 levels according to the manufacturer’s instructions (R&D Systems). Samples from 6 to 8 animals per inoculum were analyzed in triplicate. Two-way analysis of variance was used to calculate statistical differences between the groups infected with the parental strain or the B31-A3ΔrevA1ΔrevA6 mutant (P = 0.014).
### TABLE 4 Acquisition and transmission of revA-deficient mutant *B. burgdorferi* by tick feeding

<table>
<thead>
<tr>
<th>Strain</th>
<th>Acquisition by larvae as determined by:</th>
<th>Transmission from nymphs (no. of culture-positive mouse organs/total no. of organs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B31-A3</td>
<td>PCR</td>
<td>6/6 16/18</td>
</tr>
<tr>
<td>revA-deficient mutant</td>
<td>PCR</td>
<td>6/6 15/18</td>
</tr>
</tbody>
</table>

a B31-A3 and revA-deficient mutants were assessed for their abilities to be transmitted from infected mice to feeding tick larvae. Immediately after the completion of feeding, cohorts of approximately 30 engorged larvae from each mouse were analyzed by qPCR for acquisition of *B. burgdorferi*. Cohorts of larvae from B31-A3- and B31-A3ΔrevAΔrevA6 mutant-infected mice were allowed to molt. Three weeks after the molt, those ticks were allowed to feed on naïve mice. Infection was determined by detection of anti-*B. burgdorferi* IgG by ELISA and by positive culture of hearts, ears, and joints.

b PCR results are shown as positive (+) or negative (–). ELISA results are shown as the number of infected mice/total number of mice.

The relative subtlety of the effect of RevA deficiency on infection may be due to the redundancy in adhesins. To date, at least five fibronectin-binding proteins have been identified in *B. burgdorferi* (28–31), and different adhesins are likely involved in different aspects of the infection process, such as initial attachment or dissemination. For example, overexpression of BBK32 in a nonadherent *B. burgdorferi* strain enhanced bacterial binding to vascular endothelium *in vivo*, whereas similar expression of RevA did not measurably alter vascular adhesion, yet BBK32-deficient *B. burgdorferi* strains exhibit only a slight impairment in mammalian infection (24, 25, 54). The borrelial model is one of redundancy in its host-interacting proteins (e.g., adhesins and complement-regulator binding proteins [19, 65]). Only a few adhesins have been identified as absolutely essential for *B. burgdorferi* infectivity (66, 67).

It is possible that RevA has additional/other functions *in vivo*, such as immune evasion. Indeed, the increased CCL-2 levels and the defect in heart colonization seen in B31-A3ΔrevAΔrevA6-infected mice could point to differential clearance of the mutant from certain tissues early in the infection process. In contrast, there were no differences in bacterial loads in the tibiotarsal joints of mice infected with the parental strain or the revA-deficient strain. However, the revA-deficient mutant caused increased edema and fibrotic connective tissue deposition in the joint space. Here again, immune evasion could be key; the revA-deficient mutant may be inducing a more pronounced, but tissue-specific, inflammatory response that causes damage to the host while failing to clear the bacteria. Studies of the establishment and early dissemination of bacteria deficient in other adhesins, such as DbpA and BBK32, have hinted at roles in avoiding immune clearance (24, 68). Further research employing bioluminescent whole-body imaging, combined with comprehensive examination of tissue-specific pathology and immune responses, could provide insights into the role of RevA in both dissemination and colonization in the early stages of infection.

**ACKNOWLEDGMENTS**

This work was supported by NIH/NIAID grant K22AI093671 to C.A.B. We thank John Lee of the UND School of Medicine and Health Sciences, Medical Media, for expert assistance with graphics. We also thank Ann Flower and John Watt for helpful discussions.
REFERENCES


